Option chain shows key data for vTv Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for vTv Therapeutics.

vTv Therapeutics (NASDAQ:VTVT) Stock, Option Chain

vTv Therapeutics

vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.

VTVT

Biotech

News

Health Care

Movers

Trading Ideas

General

vTv Therapeutics&#39; Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month timeline to accelerate key studies.

FDA Lifts Clinical Hold On vTv Therapeutics&#39; Phase 3 Diabetes Trial, Stock Surges

Wall Street

Eurozone

Commodities

Intraday Update

Markets

CGTX

LIPO

NLSP

VERO

VTYX

Dow Edges Lower; Ventyx Biosciences Shares Plummet

movers image

AVXL

BMRC

CERO

COMM

COUR

CPTN

CTRI

IART

ITRG

LGVN

LUXH

MESO

NIPG

NISN

NOVA

NUWE

OPTT

PGHL

PHIO

PYPD

RNLX

SERV

TIVC

TNDM

TSLA

TWOU

YIBO

Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics Inc

Earnings

Press Releases

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Adicet Bio

Achilles Therapeutics plc - American Depositary Shares

Achilles Therapeutics

AlloVir

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

CytomX Therapeutics

Cue Biopharma

Fortress Biotech

Gain Therapeutics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

Immuneering Corporation - Class A Common Stock

Immuneering

IO Biotech

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Kronos Bio

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Quince Therapeutics

Shattuck Labs

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

X4 Pharmaceuticals

Exagen

Alliance Global Partners

HC Wainwright & Co.

Northland Capital Markets

Comments

vTv Therapeutics

vTv Therapeutics (VTVT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga